Summary

Smith+Nephew plc (LSE:SN.) is a FTSE 100 and FTSE 350 medical devices company specialising in orthopaedics, sports medicine and advanced wound management. The stock is in focus after FY2025 results showed 6.1% Revenue growth to $6.16bn, a 15.5% jump in trading profit, a higher Dividend and a $500m share buyback. This article explains the share price drivers, results and risks for UK investors.

Key takeaways

  • Smith+Nephew is a FTSE 100 and FTSE 350 constituent and one of the largest UK-listed medical devices companies.
  • FY2025: revenue rose 6.1% to $6,164m; underlying revenue growth was 5.3%, with all three Business units above 5%.
  • Trading profit climbed 15.5% to $1,211m, lifting trading Margin to 19.7%.
  • Orthopaedics underlying revenue grew 7.9% — the strongest quarter in over two years.
  • Total 2025 dividend raised 4.3% to 39.1 cents per share, with $500m returned via Buybacks and free Cash Flow up to $840m.

Introduction: Why Smith & Nephew shares are in focus on the FTSE 350

Smith+Nephew plc (LSE:SN.) is a leading global medical devices company and a constituent of the FTSE 100 and the wider FTSE 350. The group specialises in orthopaedics, sports medicine, ear, nose and throat, and advanced wound management. For UK investors monitoring FTSE 350 share price news and UK healthcare stocks, Smith+Nephew represents one of the most prominent pure-play medical technology names on the London Stock Exchange.

The Smith & Nephew share price has been in focus in 2025 and 2026 following a strong FY2025 results announcement. Revenue rose 6.1% to $6.16bn, with underlying growth in all three business units, trading profit jumped 15.5% to $1.21bn and the trading margin moved up to 19.7%. The Board also raised the dividend and returned $500m via share buybacks. Notably, orthopaedics delivered its strongest quarterly underlying revenue growth in more than two years, at 7.9%. This combination of recovery, margin expansion and Capital returns is what is driving renewed investor interest in the FTSE 100 medical technology stock.

Company overview: A global medical devices leader

Smith+Nephew is a global medical technology company with operations in more than 100 countries. Its core businesses include orthopaedics (knee, hip and trauma implants), sports medicine and ENT (arthroscopy, joint repair and ear/nose/throat solutions) and advanced wound management. The group’s products are used by surgeons, hospitals and clinicians to treat patients across a wide range of conditions.

Smith+Nephew is dual-listed in London and New York, with primary listing on the LSE under the ticker SN. and ADR listing on the NYSE under SNN. It is a constituent of the FTSE 100 and FTSE 350, and a long-running UK Blue-Chip. The reporting currency is the US dollar, reflecting the global nature of the business and the significant share of revenue generated in North America.

What happened: FY2025 results, dividend and buyback

The most material recent event for Smith+Nephew was the publication of its fourth quarter and full year 2025 results on 2 March 2026. According to publicly available figures, full-year revenue reached $6,164m, up 6.1% from 2024, with underlying revenue growth of 5.3%. Importantly, all three business units delivered underlying growth above 5%, with orthopaedics standing out at 7.9% — its strongest quarter of revenue growth for more than two years.

Trading profit increased 15.5% to $1,211m, lifting the trading margin to 19.7%. Free cash flow improved sharply to $840m, helped by better Working Capital Management, and adjusted ROIC rose to 8.3%. The Board increased the total 2025 dividend by 4.3% to 39.1 cents per share, and the company returned $500m via share buybacks. New 2028 targets were also outlined, signalling Board confidence in the medium-term outlook.

Why it matters for UK investors

Smith+Nephew matters for UK investors as one of the largest medical devices companies on the London Stock Exchange. As a FTSE 100 and FTSE 350 constituent, it is widely held in UK trackers, pension funds and active healthcare strategies. Its share price often acts as a barometer for broader sentiment on global elective surgery volumes, ageing demographics and orthopaedic innovation.

For UK income investors, the progressive dividend and share buybacks are also relevant, although the dollar-denominated dividend means sterling-converted distributions can vary with the GBP/USD Exchange Rate.

Latest verified update

The most material verified updates for Smith+Nephew include the FY2025 full-year results, the 4.3% dividend increase, the $500m buyback completed and the new 2028 strategic targets. Investors should consult the company’s Investor relations website and RNS announcements for the most current verified facts on results, dividends and capital plans.

Share price and investor sentiment

The Smith & Nephew share price has reflected a combination of operational recovery, margin expansion and broader healthcare sector sentiment. The FTSE 350 constituent table PDF snapshot showed a price of 1,157p, broadly consistent with trading ranges observed during 2025 and early 2026.

Investor sentiment in 2025 and 2026 has been increasingly constructive, with the strong orthopaedics print, improving margin and growing cash flow seen as evidence that strategic initiatives are bearing fruit. Sceptics still highlight execution risk, the highly competitive global orthopaedics market and the Volatility of margins as the business invests in new products and operating efficiency.

Sector and macro context: Medical devices, elective surgery and ageing populations

The medical devices sector is supported by long-term structural drivers including ageing populations, rising healthcare spending in emerging markets and ongoing innovation in surgical procedures. Demand for joint replacement surgery, in particular, has rebounded as healthcare systems work through the post-Pandemic Backlog. Robotics, digital surgery and minimally invasive techniques are reshaping orthopaedics, while advanced wound management benefits from chronic conditions such as diabetes.

Macroeconomic Factors remain important. Currency moves between the US dollar, sterling and other currencies affect reported numbers when translated for UK investors. Healthcare spending pressures, reimbursement decisions and procurement reforms can affect pricing and volumes. Supply chain costs and geopolitical risks also matter, given the global footprint of medical devices Manufacturing.

Earnings, dividends and capital returns

According to publicly available results, Smith+Nephew’s FY2025 financial profile combines mid single-digit revenue growth with double-digit profit growth and improving cash conversion. The 15.5% rise in trading profit and 70 basis point lift in trading margin to 19.7% reflect operational Leverage as the company executes its strategic plan. Free cash flow of $840m supports both the dividend and the buyback programme.

The total dividend of 39.1 cents per share, up 4.3%, is denominated in US dollars. UK investors will see sterling-converted dividend amounts based on prevailing exchange rates at the time of payment.

Broker, analyst and investor sentiment

Smith+Nephew is closely followed by UK and global Sell-Side analysts. Sentiment in 2025 and 2026 has been broadly positive, with debate over the sustainability of orthopaedics growth, the pace of margin recovery and competition from larger global medical devices peers. Without referencing specific ratings or price targets, it is fair to say Smith+Nephew remains one of the most actively analysed FTSE 350 healthcare stocks.

For specific broker views, investors should consult their own Brokers or reputable platforms such as Reuters, Bloomberg, the Financial Times, MarketWatch and Yahoo Finance UK.

Growth catalysts

Several factors could support Smith+Nephew’s Investment case. The first is continued recovery and growth in orthopaedics, particularly in the US, where elective surgery volumes have rebounded. The second is innovation in robotics (CORI surgical system) and advanced wound management products. The third is Operating Leverage from cost discipline and supply chain improvements, which can support further margin expansion.

The company’s new 2028 targets, alongside ongoing capital returns via dividends and buybacks, also support the medium-term narrative.

Risks and uncertainties

Risks include competitive pressure from larger global medical devices peers, regulatory and reimbursement changes, currency volatility, supply chain disruption and execution risk on strategic initiatives. The orthopaedics market is particularly competitive, with leading peers investing heavily in robotics and digital surgery.

What investors should watch next

UK investors monitoring the Smith & Nephew share price and FTSE 350 news may want to track quarterly and full-year results, dividend declarations, buyback execution, AGM commentary and updates on the 2028 strategic targets. Macro factors including US healthcare spending, currency moves and elective surgery volumes should also be monitored.

Conclusion

Smith+Nephew is one of the most strategically important medical devices companies on the London Stock Exchange and a key FTSE 100 and FTSE 350 constituent. FY2025 results show strong revenue and trading profit growth, improving margins, rising free cash flow and continued capital returns. Risks include competition, regulation and currency, but the long-term thesis around ageing populations, elective surgery and surgical innovation is supportive. For UK investors watching FTSE 350 share price news and UK healthcare stocks, Smith+Nephew is one of the most important names to follow.